144 related articles for article (PubMed ID: 33341677)
1. Implementation of cytogenomic microarray with plasma cell enrichment enables better abnormality detection and risk stratification in patients with plasma cell neoplasia than conventional cytogenetics and fluorescence in situ hybridization.
Chen C; Lim AST; Lau LC; Lim TH; Heng EYH; Tien SL
Cancer Genet; 2021 Apr; 252-253():25-36. PubMed ID: 33341677
[TBL] [Abstract][Full Text] [Related]
2. Assessing genome-wide copy number aberrations and copy-neutral loss-of-heterozygosity as best practice: An evidence-based review from the Cancer Genomics Consortium working group for plasma cell disorders.
Pugh TJ; Fink JM; Lu X; Mathew S; Murata-Collins J; Willem P; Fang M;
Cancer Genet; 2018 Dec; 228-229():184-196. PubMed ID: 30393007
[TBL] [Abstract][Full Text] [Related]
3. Array-based karyotyping in plasma cell neoplasia after plasma cell enrichment increases detection of genomic aberrations.
Zehentner BK; Hartmann L; Johnson KR; Stephenson CF; Chapman DB; de Baca ME; Wells DA; Loken MR; Tirtorahardjo B; Gunn SR; Lim L
Am J Clin Pathol; 2012 Oct; 138(4):579-89. PubMed ID: 23010713
[TBL] [Abstract][Full Text] [Related]
4. Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies.
Mukherjee S; Sathanoori M; Ma Z; Andreatta M; Lennon PA; Wheeler SR; Prescott JL; Coldren C; Casey T; Rietz H; Fasig K; Woodford R; Hartley T; Spence D; Donnelan W; Berdeja J; Flinn I; Kozyr N; Bouzyk M; Correll M; Ho H; Kravtsov V; Tunnel D; Chandra P
Cancer Genet; 2017 Oct; 216-217():128-141. PubMed ID: 29025587
[TBL] [Abstract][Full Text] [Related]
5. Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms.
Lu G; Muddasani R; Orlowski RZ; Abruzzo LV; Qazilbash MH; You MJ; Wang Y; Zhao M; Chen S; Glitza IC; Medeiros LJ
Arch Pathol Lab Med; 2013 May; 137(5):625-31. PubMed ID: 23627452
[TBL] [Abstract][Full Text] [Related]
6. Risk stratification of plasma cell neoplasm: insights from plasma cell-specific cytoplasmic immunoglobulin fluorescence in situ hybridization (cIg FISH) vs. conventional FISH.
Dong H; Yang HS; Jagannath S; Stephenson CF; Brenholz P; Mazumder A; Chari A
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):366-74. PubMed ID: 22658896
[TBL] [Abstract][Full Text] [Related]
7. The success rate of interphase fluorescence in situ hybridization in plasma cell disorders can be improved using unconventional sources of plasma cells.
Panakkal V; Rana S; Rathore S; Anshu A; Balakrishnan A; Singh C; Jandial A; Sachdeva MUS; Varma N; Lad D; Malhotra P; Sreedharanunni S
Int J Lab Hematol; 2022 Feb; 44(1):157-162. PubMed ID: 34636141
[TBL] [Abstract][Full Text] [Related]
8. Chromosomal microarray analysis is superior in identifying cryptic aberrations in patients with acute lymphoblastic leukemia at diagnosis/relapse as a single assay.
Chen C; Heng EYH; Lim AST; Lau LC; Lim TH; Wong GC; Tien SL
Int J Lab Hematol; 2019 Aug; 41(4):561-571. PubMed ID: 31112375
[TBL] [Abstract][Full Text] [Related]
9. Prognostic classification of MDS is improved by the inclusion of FISH panel testing with conventional cytogenetics.
Kokate P; Dalvi R; Koppaka N; Mandava S
Cancer Genet; 2017 Oct; 216-217():120-127. PubMed ID: 29025586
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in cytogenetic characterization of multiple myeloma.
Saxe D; Seo EJ; Bergeron MB; Han JY
Int J Lab Hematol; 2019 Feb; 41(1):5-14. PubMed ID: 29971938
[TBL] [Abstract][Full Text] [Related]
11. A Novel Integrated Approach for Cytogenomic Evaluation of Plasma Cell Neoplasms.
Aarabi M; Yoest JM; Farah R; Rajkovic A; Swerdlow SH; Yatsenko SA
J Mol Diagn; 2022 Oct; 24(10):1067-1078. PubMed ID: 35940519
[TBL] [Abstract][Full Text] [Related]
12. Cytogenetic testing by fluorescence in situ hybridization is improved by plasma cell sorting in multiple myeloma.
Ha J; Cho H; Lee TG; Shin S; Chung H; Jang JE; Kim SJ; Cheong JW; Lee ST; Kim JS; Choi JR
Sci Rep; 2022 May; 12(1):8287. PubMed ID: 35585097
[TBL] [Abstract][Full Text] [Related]
13. [A comparative study of fluorescence in situ hybridization versus conventional cytogenetics in the detection of clonal aberrations in myelodysplastic syndrome].
Lai YY; Li N; Feng L; Shi Y; Dang H; He Q; Wang Z; Wang XY; Li Y; Liu Q; Huang XJ
Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(40):3175-9. PubMed ID: 24405535
[TBL] [Abstract][Full Text] [Related]
14. FISH and FICTION in Lymphoma Research.
Giefing M; Siebert R
Methods Mol Biol; 2019; 1956():249-267. PubMed ID: 30779038
[TBL] [Abstract][Full Text] [Related]
15. Fluorescence in situ hybridization (FISH) in cytogenetics of leukemia.
Michalová K
Folia Biol (Praha); 1996; 42(6):311-4. PubMed ID: 9158941
[TBL] [Abstract][Full Text] [Related]
16. Modified Culture System and Combination of FICTION Could Increase the Detection Rate of Abnormalities in Multiple Myeloma.
Fu Q; Xie S; Chen J; Huang H
Ann Clin Lab Sci; 2021 Jan; 51(1):61-72. PubMed ID: 33653782
[TBL] [Abstract][Full Text] [Related]
17. Detection of genomic abnormalities in multiple myeloma: the application of FISH analysis in combination with various plasma cell enrichment techniques.
Hartmann L; Biggerstaff JS; Chapman DB; Scott JM; Johnson KR; Ghirardelli KM; Fritschle WK; Martinez DL; Bennington RK; de Baca ME; Wells DA; Loken MR; Zehentner BK
Am J Clin Pathol; 2011 Nov; 136(5):712-20. PubMed ID: 22031309
[TBL] [Abstract][Full Text] [Related]
18. Fluorescent in situ hybridization as an adjunct to conventional cytogenetics.
Mark HF
Ann Clin Lab Sci; 1994; 24(2):153-63. PubMed ID: 8203823
[TBL] [Abstract][Full Text] [Related]
19. Phase determination using chromosomal microarray and fluorescence in situ hybridization in a patient with early onset Parkinson disease and two deletions in PRKN.
Williams ES; Barrett MJ; Dhamija R; Toran L; Chambers C; Mahadevan MS; Golden WL
Mol Genet Genomic Med; 2018 May; 6(3):457-462. PubMed ID: 29577677
[TBL] [Abstract][Full Text] [Related]
20. Interphase fluorescence in situ hybridization analysis of CD19-selected cells: Utility in detecting disease in post-therapy samples of B-cell neoplasms.
Parrott AM; Murty VV; Walsh C; Christiano A; Bhagat G; Alobeid B
Cancer Med; 2021 Apr; 10(8):2680-2689. PubMed ID: 33724696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
